A Phase I, Multicenter, Open label does escalation Safety Pharmacokinetic and Pharmacodynamic Study of Minnelide given daily for 21 days followed by 7 days off schedule in patients with Advanced GI Tumors
|Effective start/end date||8/8/13 → 8/30/18|
- MINNEAMRITA THERAPEUTICS, LLC
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.